Special Issue

Natural and Synthesized Anticancer Bioactive Compounds in Drug Discovery, Formulations and Delivery

Message from the Guest Editor

This Special Issue has the aim of covering current research and current approaches to the design and development of anticancer drugs. The discovery of natural and synthetic bioactive compounds with strong cytotoxic activity may represent a starting point for the development of several promising preclinical candidates for cancer treatment. Isolation of bioactive compounds, as well as the synthesis and design of compounds based on state-of-the-art tools, computational modeling studies, artificial intelligence, and machine learning techniques, will provide an understanding of disease mechanisms, and progress in cancer drug discovery. On the other hand, targeted drug delivery and the use of colloidal delivery systems such as nanoparticles, liposomes, micelles, and dendritic biopolymers have drawn significant attention. In addition, so far, it has been confirmed that many of the molecular target changes have been shown at the level of gene expression, and thus, that the effects of bioactive compounds may be mediated by the induction or repression of gene expression via direct molecular interaction (signaling pathways, transcription factors) or, most likely, by epigenetic mechanisms.

Guest Editor

Prof. Dr. Tatjana P. Stanojković Institute of Oncology and Radiology of Serbia, Pasterova 14, 11000 Belgrade, Serbia

Deadline for manuscript submissions

closed (15 December 2022)



an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



mdpi.com/si/111631

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

mdpi.com/journal/pharmaceutics





an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Department of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ 08854, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).

